Tuberculosis remains a significant cause of morbidity and mortality globally, despite concerted health policy efforts in Algeria. In recent years, there has been a concerning rise in the incidence of both pulmonary and extra-pulmonary tuberculosis. Our study, conducted at the SCTMR laboratory in Ras-El-Oued, spanned the years 2018 (137 samples) and 2019 (76 samples).The most affected demographic comprised young adults aged between 15 and 65 years, with women being disproportionately affected. Clinical presentation often includes symptoms such as fever, cough, weight loss, fatigue/weakness, night sweats, and anorexia. Treatment primarily involved anti-tuberculosis drugs, including Isoniazid, Rifampicin, and Pyrazinamid, known for their anti bacillary activity. Microscopic examination was employed as the primary diagnostic technique for tuberculosis detection. In 2018, the study recorded a cure rate of 49.4%, completion of treatment (without control culture) at 42.9%, and mortality at 7.8%. Regarding specific manifestations, over 35.4% of cases of lymph node TB exhibited fibrous scar-pleural squeal with axillary diameter within the range of ]15mm; 20mm], while pleural TB accounted for 11.1% of cases with axillary diameter less than 15mm. The mortality rate for lymph node TB was 1.2%. Enhanced understanding of tuberculosis and its treatment is pivotal in promoting adherence to screening among contacts and fostering better compliance with treatment regimens. This approach is crucial for reducing the risk of tuberculosis development, both on an individual level and from a public health perspective.